High Flow Nasal Cannula vs NPPV in Moderate Chronic Obstructive Pulmonary Disease Exacerbation

Recruiting in Palo Alto (17 mi)

Overseen ByQingyuan Zhan, M.D.

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: China-Japan Friendship Hospital

No Placebo Group

Trial Summary

What is the purpose of this trial?For moderate AECOPD(pH\<7.35), several guidelines have strongly recommended NPPV as standard therapy, which can reduce the rate of intubation and mortality. A few previous studies have shown that HFNC can efficiently improve alveoli ventilation and breathing pattern in some severe AECOPD patients. Therefore, we hypothesize that HFNC is not inferior to NPPV for preventing endotracheal intubation in moderate AECOPD patients. To assess this hypothesis, we performed a multicenter, randomized, noninferiority trial of HFNV vs NPPV in moderate AECOPD patients.

Eligibility Criteria

Inclusion Criteria

AECOPD; 7.35>pH≥7.25，PaCO2>50 mmHg

Participant Groups

2Treatment groups

Experimental Treatment

Active Control

Group I: High flow nasal cannulaExperimental Treatment1 Intervention

High flow nasal cannula(OptiflowTM); Flow 25-60 L/min is set according to patients' comfort; FiO2 is adjusted to maintain peripheral capillary oxygen saturation(SpO2) 90-95%; temperature is set at 37 degree centigrade.

Group II: Noninvasive positive ventilationActive Control1 Intervention

Parameters are set according to NPPV protocols